Lung cancer is the most common cause of cancer-related deaths worldwide, as 2.1 million people were diagnosed with disease and 1.8 passed away from lung worldwide in 2018.[1] The condition split into two sections: Small Cell Cancer (SCLC) Non-Small (NSCLC). In this research paper, I discuss key aspects NSCLC, including risk factors, symptoms, diagnosis, treatment, prevention, epidemiology. Last...

Objective(s): Non-small cell lung cancer (NSCLC) has become a serious global health problem in the 21st century, and tumor proliferation and metastasis are the leading causes of death in patients  with lung cancer. The present study aimed to verify the function of miR-96 and miR-96 in relation to competing with endogenous RNA regulatory network in NSCLC progression inc...

Background: Skeletal muscle radiodensity is associated with postoperative complications in cancer. However, data on skeletal and complication risk patients non-small cell lung cancer (NSCLC) are scarce, this study investigated the relationship between NSCLC treated by thoracoscopic lobectomy.

Ferroptosis therapy gradually becomes a new strategy for the treatment of non-small cell lung cancer (NSCLC) because its active iron metabolism. Because hypoxic microenvironment in NSCLC inhibits ferroptosis heavily,...

Background: Lung cancer is a leading cause of cancer-related mortality worldwide. The purpose our meta-analysis was to assess the risk factors for brain metastases (BM) in patients with non-small cell lung (NSCLC).

Background: Radiotherapy is the gold standard in the treatment of lung cancer. However, the radiosensitization of cancerous cells requires further improvement. Here, we investigated the effect of dihydroartemisinin (DHA) on the radiosensitization of non-small cell lung cancer (NSCLC) cells. Methods: Cell proliferation and cell cycle assays were carried out using A549 cells exposed to DHA. The e...

Testing for driver mutations in non-squamous non-small cell lung cancer (NSCLC) before treatment is recommended. Next Generation Sequencing (NGS) allows simultaneous testing of multiple genes. NGS results NS-NSCLC Lebanon have not yet been reported.

Background: Immune checkpoint inhibitors (ICIs) have become the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). However, safety and efficacy of ICIs in severe NSCLC poor performance status (PS) are still unclear.

Background: We performed a retrospective analysis to determine the incidence of neurotrophic tropomyosin-receptor kinase (NTRK) fusion in non-small cell lung cancer (NSCLC).